NCT00230321 - A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

November 30, 2007

Study Completion Date

January 31, 2008

Conditions

Blood CancerMyelodysplastic SyndromesMyelodysplastic Syndromes (MDS)

Interventions

DRUG

Darbepoetin alfa

During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford